Valuation: Arrowhead Pharmaceuticals, Inc.

Market Cap 8.46B 7.58B 6.97B 6.32B 11.81B 803B 12.03B 83.12B 33.37B 423B 31.75B 31.08B 1,333B P/E 2026 *
-16.6x
P/E 2027 * -12.8x
Enterprise Value 7.63B 6.83B 6.28B 5.69B 10.64B 724B 10.84B 74.95B 30.09B 381B 28.63B 28.02B 1,202B EV / Sales 2026 *
16.4x
EV / Sales 2027 * 23.7x
Free-Float
94.56%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Arrowhead Pharmaceuticals, Inc.

1 day-0.98%
1 week+3.24%
1 month-8.48%
3 months-29.24%
6 months-18.48%
Current year-9.78%
1 week 58.01
Extreme 58.01
61.88
1 month 55.83
Extreme 55.83
66.16
Current year 54.02
Extreme 54.02
95.49
1 year 37.06
Extreme 37.06
95.49
3 years 9.57
Extreme 9.57
95.49
5 years 9.57
Extreme 9.57
95.49
10 years 1.2
Extreme 1.2
95.49
Manager TitleAgeSince
Chief Executive Officer 56 01/12/2007
Director of Finance/CFO - 13/05/2025
Chief Tech/Sci/R&D Officer - 01/08/2022
Director TitleAgeSince
Chairman 56 -
Director/Board Member 66 19/08/2010
Director/Board Member 66 19/12/2011
Date Insider Type Main position Quantity % Market Cap. Importance
18/08/26 Sell

Director

-2,000 0.0014%
18/08/26 Sell

Director

-11,600 0.0082%
15/06/26 Free

Director

11,882 0.0084%
Change 5-day change 1-year change 3-year change Capi.($)
-0.98%+3.24%+41.31%+143.59% 8.46B
-0.62%-1.87%+42.87%+64.15% 63.77B
+0.35%+3.20%+14.40%+81.76% 56.37B
+0.53%+1.96%+16.24%+103.35% 54.62B
-2.81%-4.31%+23.50%+47.83% 44.06B
-0.33%-1.93%+19.28%+98.80% 42.11B
+0.55%+2.31%+225.14%+866.21% 41B
+3.27%+47.96%+112.84%+96.58% 34.92B
+1.22%-1.44%+14.57%+46.95% 32.82B
+0.89%+20.55%-40.62%+349.24% 24.7B
Average +0.21%+7.11%+46.95%+189.85% 40.28B
Weighted average by Cap. +0.15%+5.40%+47.85%+175.98%

Financials

2026 *2027 *
Net sales 464M 416M 382M 346M 648M 44.07B 660M 4.56B 1.83B 23.18B 1.74B 1.7B 73.11B 328M 294M 270M 245M 458M 31.17B 467M 3.22B 1.29B 16.39B 1.23B 1.21B 51.7B
Net income -513M -459M -422M -383M -715M -48.67B -729M -5.04B -2.02B -25.6B -1.92B -1.88B -80.74B -663M -594M -546M -495M -925M -62.97B -943M -6.52B -2.62B -33.13B -2.49B -2.44B -104B
Net Debt -832M -745M -686M -621M -1.16B -79.03B -1.18B -8.18B -3.28B -41.57B -3.12B -3.06B -131B -683M -612M -562M -510M -953M -64.83B -971M -6.71B -2.69B -34.1B -2.56B -2.51B -108B
Projected Income Statement - Annual - Arrowhead Pharmaceuticals, Inc.
Logo Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. Its Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, neuromuscular and others. It has over 18 discovered drug candidates in clinical trials ranging from early stage (Phase I) to late stage (Phase III). The Company's pipeline products include plozasiran, zodasiran, olpasiran, ARO-RAGE, SRP-1002, GSK4532990, fazirsiran, daplusiran/tomligisiran, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, SRP-1001 (ARO-DUX4), SRP-1003 (ARO-DM1), SRP-1004 (ARO-ATXN2), and others.
Employees
711
Date Price Change Volume
30/10/26 $59.90 -0.98% 1,124,656
29/10/26 $60.49 +0.47% 1,275,721
28/10/26 $60.21 +2.00% 1,248,403
27/10/26 $59.03 +0.08% 2,118,861
26/10/26 $58.98 +1.65% 979,892
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Arrowhead Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
59.90USD
Average target price
107.71USD
Spread / Average Target
+79.82%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Arrowhead Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. ARWR Stock